Akero Therapeutics Inc (NASDAQ:AKRO) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Drive Investor Optimism

Akero Therapeutics Inc (NASDAQ:AKRO) reported its second-quarter 2025 financial results, with a net loss of $70.5 million, or $0.86 per share, compared to a net loss of $56.0 million, or $0.81 per share, in the same quarter last year. The company’s loss per share was narrower than analyst estimates of -$0.91, while revenue remained in line with expectations at $0.0, as Akero is still in the clinical-stage and has no commercialized products.

Market Reaction

The stock saw a pre-market gain of approximately 6.5%, reflecting investor optimism following the earnings beat on EPS. Over the past month, shares have declined nearly 3%, but the positive reaction to the Q2 report suggests renewed confidence in the company’s clinical progress and financial position.

Key Highlights from the Earnings Report

• Clinical Advancements: The company highlighted the publication of 96-week Phase 2b SYMMETRY trial results in the New England Journal of Medicine, demonstrating efruxifermin’s (EFX) ability to reverse compensated cirrhosis (F4) due to metabolic dysfunction-associated steatohepatitis (MASH).
• EASL Congress Presentations: Three presentations at the European Association for the Study of the Liver (EASL) Congress 2025 reinforced EFX’s anti-fibrotic effects in both cirrhotic (F4) and pre-cirrhotic (F2-F3) MASH patients.
• Phase 3 Progress: Akero anticipates preliminary results from its SYNCHRONY Real-World trial in the first half of 2026, followed by SYNCHRONY Histology data in early 2027.
• Strong Cash Position: The company reported $1.09 billion in cash and marketable securities, providing runway into 2028.

Financial Overview

• Operating Expenses: Increased to $80.9 million in Q2 2025, up from $65.7 million in Q2 2024, driven by higher R&D costs for Phase 3 trials and manufacturing scale-up.
• Net Loss: Narrowed by 6% year-over-year, helped by higher interest income.

Looking Ahead

Analysts estimate a Q3 2025 loss per share of -$0.99, with full-year 2025 projections at -$3.95. While Akero did not provide explicit financial guidance, its robust cash reserves and advancing clinical programs position it as a key player in the MASH treatment landscape.

For more detailed earnings estimates and historical performance, view the full earnings analysis here.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research before making any financial decisions.